Benzinga - by Avi Kapoor, Benzinga Staff Writer.
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Realty Income (NYSE: O) and recommends staying with it. "It’s a very steady story," he noted.
When asked about ImmunoGen, Inc. (NASDAQ: IMGN), he said, "That’s AbbVie’s (NYSE: ABBV) property now, let’s move on."
Cramer said he is not a buyer of Ramaco Resources, Inc. (NASDAQ: METC). "Let it go up without me," he added.
Don’t forget to check out our premarket coverage here
The "Mad Money" host said he doesn’t really know Bitfarms Ltd. (NASDAQ: BITF). "I just feel like it’s just speculative," he added.
"I think the stock can tread water or go back to the high seventies," Cramer said when asked about Micron Technology, Inc. (NASDAQ: MU).
Cramer said Coherent Corp. (NYSE: COHR) is a "little too expensive."
GE HealthCare Technologies Inc. (NASDAQ: GEHC) is "ridiculously cheap," Cramer said, "I think it’s doing so many great things."
When asked about TKO Group Holdings, Inc. (NYSE: TKO), he said, "I actually don’t understand how to value this company."
Arm Holdings plc (NASDAQ: ARMH) is "one you want to own," he said. "I think Rene Haas [CEO of ARM] is doing a fantastic job."
On Nov. 8, the chipmaker reports earnings for the first time since its initial public offering in September.
Cramer said he is not a Teva Pharmaceutical Industries Limited (NYSE: TEVA) guy.
Price Action: Shares of Teva gained 4.1% to close at $11.33, while Arm Holdings fell 2% to $67.05 on Friday. TKO fell 0.3% to settle at $78.63, while GE HealthCare gained 0.1% to $76.62 during Friday’s session. Coherent shares gained 1.4% to settle at $41.17, while Micron rose 0.9% to close at $83.45 on Friday. Bitfarms shares fell 7.2%, while Ramaco Resources fell 1.2%. ImmunoGen shares gained 0.4%, while AbbVie gained 0.4% on Friday. Shares of Realty Income rose 0.4% to close at $57.92 during Friday’s session.
Now Read This: How To Earn $500 A Month From Conagra Brands Stock Following Latest Earnings Report
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.